TAR DNA binding protein 43 (TDP-43) is a major disease-associated protein involved in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U). Our previous studies found a direct association between TDP-43 and heterogeneous nuclear ribonucleoprotein K (hnRNP K). In this study, utilizing ALS patient fibroblasts harboring a TDP-43 M337V mutation and NSC-34 motor neuronal cell line expressing TDP-43 Q331K mutation, we show that hnRNP K expression is impaired in urea soluble extracts from mutant TDP-43 cell models. This was confirmed in vivo using TDP-43 Q331K and inducible TDP-43 A315T murine ALS models. We further investigated the potential patho- 
Introduction
Amyotrophic lateral sclerosis (ALS) is a chronic adult-onset motor neuron disease (MND) that causes death of lower motor neurons in the brainstem and spinal cord, and of upper motor neurons in the motor cortex. The resulting motor neuron loss leads to muscle atrophy and weakness, fasciculations, spasticity and death typically from respiratory failure (1) . Neurons in the prefrontal and temporal cortex are also affected in approximately 15% of patients with ALS in which degeneration of neurons results in frontal executive dysfunction and concurrent frontotemporal lobar degeneration (FTLD). This is known as ALS with FTLD. Despite clear clinico-pathological differences, these disorders share a high degree of co-morbidity and therefore represent a spectrum of related disorders (2) . ALS affects approximately two individuals per 100,000 per year. While the disease course may vary drastically among patients, once afflicted, the average survival is approximately 3-5 years from symptom onset (3) .
While ALS is a multifactorial disease, recent genetic breakthroughs have identified a number of known mutations causing familial ALS (fALS), among them mutations in genes coding for superoxide dismutase 1 (SOD1), transactivation response TAR DNA-binding protein (TARDP), fused-in sarcoma/translocation in liposarcoma (FUS/TLS), and, most recently, hexanucleotide repeat (GGGGCC) within the chromosome 9 open reading frame 72 (C9ORF72) gene, which is the most common cause of fALS (4) (5) (6) . The identification of Transactivation response DNAbinding protein-43 (TDP-43), which belongs to the family of heterogeneous nuclear ribonucleoproteins (hnRNPs), as a major protein component of ubiquitinated inclusions in ALS and FTLD-U patients has focused research on the role of hnRNP accumulation in these diseases.
hnRNPs are a large family of proteins that associate with nascent pre-mRNAs, packaging them into hnRNP complexes. Structurally, all hnRNPs contain one or more RNA-binding domains, such as RNA-recognition motifs (RRMs), which facilitate specific binding to RNA sequences. TDP-43 is a predominantly nuclear protein, although it can shuttle between the nucleus and cytosol governing RNA processing including transcription, pre-mRNA splicing, transport and stabilization of mRNA (7, 8) . In ALS and FTLD-U post-mortem CNS tissues, TDP-43 accumulates predominantly as a C-terminal fragment of 25 or 35 kDa in cytosolic inclusions. The aggregated TDP-43 is also posttranslationally modified, being heavily ubiquitinated, and phosphorylated at the C-terminal region (9) . Numerous studies have identified missense mutations in the C-terminal region in fALS and sporadic ALS (sALS) cases, and, to date, over 50 mutations in TARDBP have been identified. Despite the identification of TDP-43 as a hallmark of cytoplasmic inclusions in ALS, it remains unclear whether motor neuron degeneration in ALS occurs because of the depletion of nuclear TDP-43, the gain of a toxic function of cytoplasmic TDP-43, or a combination of these processes.
Supporting the role of RNA binding proteins in ALS pathology, missense mutations in the prion like domains (PrLD) of hnRNP A1 and hnRNP A2/B1 were identified in cases of fALS patients. These missense mutations accelerated hnRNP A1 and hnRNP A2 fibrilization, which are TDP-43 binding partners, and also promoted potent steric zippers in the PrLDs, increasing the propensity of the proteins to form fibrils and cytoplasmic inclusions, which were also immunoreactive for TDP-43 (10, 11) . In animal models that emulate the ALS phenotype, the disease mutations promoted the excess incorporation of hnRNPA1 and hnRNPA2 into stress granules and this promoted the formation of cytoplasmic inclusions (10) . The identification of multiple RNA binding proteins frequently mutated in ALS has placed them at a pivotal point in disease etiopathology and has led to ALS being categorized as an RNA misprocessing disease.
There are many facets that contribute to the etiopathology of ALS, with impaired signaling pathways such as oxidative stress, excitotoxicity, neuroinflammation and mitochondrial dysfunction all linked to ALS pathology (12) (13) (14) (15) . An imbalance between the generation of reactive oxygen species (ROS) and their removal, and/or the ability of the biological system to remove or repair ROS-induced damage can result in oxidative stress (16) . Nuclear factor erythroid-2-related factor 2 (Nrf2), a basic region leucine-zipper transcription factor is considered the master regulator of the phase II antioxidant response and responds to oxidative stress by binding to and upregulating antioxidant response elements (ARE) (17) . Analyses of cerebrospinal fluid (CSF) and human post-mortem CNS tissue have shown the presence of biochemical changes as a result of free radical damage or abnormal free radical metabolism, with alterations more robust in ALS cases than in controls (18) (19) (20) . Additionally, elevated levels of oxidative damage to proteins, lipids and DNA have been found in post-mortem tissue from sALS and SOD1 linked fALS cases (18, 21) . Despite this presence of oxidative stress, Nrf2 signaling is impaired in models of SOD1-related ALS and in the CNS of ALS patients (22) . Therefore, Nrf2 function appears to be impaired in ALS, which may have a significant role in ALS pathology. Up-regulating Nrf2 activity is a major therapeutic target for ALS and other neurodegenerative diseases (17, 23) . Likewise, whether a direct relationship exists between Nrf2, antioxidant response, and hnRNPs in ALS is not known. There have been no reports directly linking hnRNPs with Nrf2 or modulation of its downstream antioxidant targets.
hnRNP K is an evolutionarily conserved RNA binding protein predominantly localized in the nucleus where it can modulate gene expression pathways such as chromatin remodeling, transcription, mRNA splicing, export, and translation (24) . A proteomics analysis has identified hnRNP K as a binding partner of TDP-43 (25) . This was further confirmed in our recent study demonstrating that hnRNP K and TDP-43 interact directly or indirectly in the cytosol (26) . We have previously reported that phosphorylation of hnRNP K by cyclin dependant kinase 2 (CDK2) is required for modulating the cytosolic accumulation of TDP-43 into stress granules. In light of this, we hypothesized that mutations in TDP-43 may influence the expression of hnRNP K and the RNA binding properties of the protein, leading to the pathological features of ALS. In the current study, we further investigated the relationship between TDP-43 and hnRNP K in ALS and we identify that hnRNP K expression and localisation is altered in TDP-43 patient fibroblasts and in TDP-43 mouse models of ALS. In order to determine if these changes have a pathological role in ALS, we examined whether hnRNP K binds to key RNA transcripts and how this is affected in the disease context. RNA binding immunoprecipitation studies in patient fibroblasts revealed robust enrichment of NFE2L2 (Nrf2) and GPX1 (glutathione peroxidase 1) transcripts bound to hnRNP K protein in TDP- 43 
Results

Cell stress induces loss of hnRNP K protein expression
We have previously reported that hnRNP K consistently colocalizes with TDP-43 in cytoplasmic RNA stress granules, which are sites of stalled mRNA translation initiation complexes, formed in response to stress in neuronal cell culture models (26, 27) . Stress granules are also thought to be early precursors to ubiquitinated protein aggregates, which are a hallmark feature of ALS (28) . We have also reported that hnRNP K is a binding partner of TDP-43, reinforcing that these two RNA binding proteins are closely linked in their cellular function(s) (26) . To further examine the expression of hnRNP K in models of ALS, we analysed the protein expression of hnRNP K in patient fibroblasts harbouring a TDP-43 M337V mutation before and after symptom onset relative to a matched healthy control. While these cells are non-neuronal, they are a valuable tool to study the biology of hnRNP K in ALS, as the mutant form of TDP-43 is endogenously expressed (29) . We have previously used agents such as the mitochondrial inhibitor paraquat and sodium arsenite, another mitochondrial toxin, to induce TDP-43 and hnRNP K accumulation into stress granules (26, 30, 31) . Here, we applied sodium arsenite to TDP-43 M337V and control fibroblasts at a concentration of 300 lM for 3h, which does not compromise the viability of the cells (Supplementary Material, Fig. S1A and B), We found that in response to stress induced by sodium arsenite, hnRNP K expression in whole cell extracts was attenuated in both control and mutant fibroblasts, Fig. 1A . Other hnRNPs analysed including TDP-43, hnRNP A2 and hnRNP A3 displayed a similar pattern of expression however, hnRNPA1 remained relatively unchanged and interestingly FUS displayed greater expression in TDP-43 M337V patient fibroblasts compared to controls and was not affected by sodium arsenite (Fig. 1A) .
To determine if the expression of hnRNP K in response to stress was consistent in another cell model of TDP-43 pathology, we examined NSC-34 motor neuronal cells stably transfected with mCherry only (vector control, VC) or mCherrytagged with full length human TDP-43, either wild-type (WT), or TDP-43 Q331K (Fig. 1B) . Stress induced by sodium arsenite at a concentration of 300 lM for 3h resulted in reduced hnRNP K expression in VC, WT TDP-43 and TDP-43 Q331K expressing cells (Fig. 1C) . We then examined gene expression of hnRNPs and interestingly, the gene expression of hnRNP K in both patient fibroblasts and in NSC-34 cells harbouring TDP-43 mutations displayed attenuated expression compared to controls after induction of a stress response induced by sodium arsenite ( Fig. 1D and E). As the hnRNP K gene expression levels were measured after only 3h exposure to sodium arsenite, this was unlikely to contribute to the changes in hnRNP K protein levels observed, but may indicate that stress induction could lead to impaired hnRNP K levels through loss of gene expression in cells with mutant TDP-43 at later time points not examined here. This is consistent with our observation of reduced hnRNP K expression in motor neurons of ALS patients (26) . There was also stressmediated loss of hnRNPs A1, A2 and A3 gene expression, with greater loss in mutant fibroblasts ( pre-symptomatic and postsymptomatic patient fibroblasts compared to control fibroblasts under basal conditions however the nuclear expression of hnRNP K was significantly increased in both mutant and control fibroblasts in response to sodium arsenite treatment ( Fig. 2A,  Supplementary Material, Fig. S3A ). Two additional patient control cells were also analysed and displayed similar pattern of expression of hnRNP K (Supplementary Material, Fig. S4 ). Under basal conditions TDP-43 expression was unchanged in all fibroblast lines, however response to sodium arsenite was similar to hnRNP K ( Fig. 2A, Supplementary Material, Fig. S3B ). We also analyzed the expression of hnRNP A1, A2 and A3 in the cytoplasmic and nuclear extracts where we observed an overall reduction in the cytoplasmic expression of hnRNPA1, A2 and A3 in response to sodium arsenite in all fibroblast lines analysed, except for cytoplasmic hnRNP A3 in post-symptomatic patient fibroblasts where levels were relatively unchanged in response to sodium arsenite ( Fig. 2A, Supplementary Material, Fig. S3C-E ). Opposite to hnRNP K, we did not observe any significant changes in the nuclear expression of hnRNP A1 in postsymptomatic patient fibroblasts ( Fig. 2A, Supplementary  Material, Fig. S3C ). Interestingly, the basal nuclear expression levels of hnRNP A2 was significantly attenuated in postsymptomatic patient fibroblasts compared to control and pre-symptomatic fibroblasts ( Fig. 2A, Supplementary Material,  Fig. S3D ). However, the nuclear expression of hnRNP A3 did not parallel that of hnRNP K in the nucleus, with no significant increase in the mutant fibroblasts compared to control in response to sodium arsenite ( Fig. 2A, Supplementary Material, Fig. S3E ). We did not observe any striking changes in the nuclear expression of FUS in all fibroblast lines analysed ( Fig. 2A,  Supplementary Material, Fig. S3F ).
To determine if TDP-43 M337V mutation influences the solubility of hnRNP K and the propensity of the protein to aggregate, we analysed the expression of hnRNP K and additional hnRNPs in sequential RIPA and urea extractions. While the formation of higher order aggregates was not evident for any hnRNPs analysed, we observed a substantial decrease in the expression of hnRNP K in both RIPA soluble and RIPA insoluble (urea) extracts in pre and post-symptomatic TDP- TDP-43 Q331K mutation and inducible TDP-43 (iTDP-
43) A315T mutation induces loss of insoluble hnRNP K in mouse brain
To determine if similar changes to hnRNP K occur in vivo, we examined transgenic mice expressing mutant TDP-43 Q33IK in the central nervous system under regulation of the mouse prion protein promoter (mPrP) as previously described (32, 33) . Mice expressing mutant TDP-43 display age related motor deficits (32) . We first extracted total protein from brains of control and TDP-43 Q331K transgenic mice (12 months of age) and examined the expression of hnRNPs A1, A2, A3 and K. We observed no striking changes in the expression of these proteins in total cell extracts ( Fig. 3A) . We next extracted proteins from brains of control and TDP-43 Q331K transgenic mice followed by sequential RIPA and urea extractions as previously reported (34) . We found significant loss of hnRNP K in detergent insoluble material in WT and transgenic mice, however the loss of hnRNP K in Tg mice was more robust ( 
hnRNP K gene expression is altered in FTLD-TDP-43 human brain
Based on our findings, we theorized that HNRNPK gene expression may be changed in patients with mutated TDP-43 but not sporadic cases without TDP-43 mutation. To examine this, we investigated HNRNPK gene expression in a cohort of FTLD cases that had TDP-43 aggregation but no TDP-43 mutations (for a detailed list of cases, refer to reference (35) . Both FTLD and ALS are heterogeneous at the clinical, neuropathological and genetic level and while they appear to be distinct progressive disorders, there is recurring evidence that they share some common clinical, neuropathological and genetic features. This suggests that these two neurological disorders may be part of a common hnRNP K protein was purified from the cell lines (Fig. 4A ), followed by analysis of RNA transcripts bound to the protein by a customized array of genes known to be associated with neurodegeneration. The array comprised of 92 genes with relevance to oxidative stress, mitochondria, ubiquitination and apoptosis (refer to Supplementary Material, Table S1 for a complete list of genes analysed). Prior to carrying out the customized array, we confirmed the quality of the purified RNA by carrying out quality control experiments as described in the materials and method section and also analysed the enrichment of early growth response 1 (EGR1) via qRT-PCR, as hnRNP K has been previously reported to bind to the 3' end of the EGR1 transcript (36) . While enrichment of EGR1 was observed in all cell lines analysed (control, pre and post-symptomatic TDP-43 M337V patient fibroblasts), we detected significant enrichment of EGR1 in pre and post symptomatic patient fibroblasts treated with sodium arsenite compared to controls (Supplementary Material, Fig. S9 ).
We next carried out analysis with the customized gene array and we detected a robust set of differentially enriched genes in pre and post-symptomatic TDP-43 M337V patient fibroblasts compared to controls. Of the 92 genes analyzed (Supplementary Material, Table S1 ), 30 genes showed at least a 2-fold increase in enrichment relative to IgG rabbit negative control. Of particular interest were genes associated with oxidative stress, neurodegeneration, ubiquitin and proteasomal degradation pathway, and apoptosis (Fig. 4B) . We focused our attention on NFE2L2 and GPX1 as these genes encode key antioxidant proteins Nrf2 and glutathione peroxidase 1 respectively. Nrf2 is a transcription factor considered to be the master regulator of the phase II antioxidant response and a critical mediator of antioxidant gene expression (17) . Therefore, it is prominently regarded as a major neuroprotective molecule in neurodegenerative diseases (23). GPx1 is a major intracellular antioxidant enzyme and key regulator of redox balance (37) . In cell models and transgenic mouse models, overexpression of GPx1 is associated with greater protection against oxidative stress insults (38,39). We observed significant enrichment of NFE2L2 and GPX1 bound to hnRNP K in post-symptomatic patient fibroblasts compared to control and exposure to stress induced by sodium arsenite greatly enriched the binding of the transcripts to hnRNP K in all cells, (Fig. 4C) . We determined the transcript expression of antioxidant genes NFE2L2 (Fig. 4D) , HMOX1 (Fig. 4E) and GPX1 (Fig. 4F ) in patient fibroblasts and we observed a substantial increase in the expression of the anti-oxidant genes in response to stress, in particular, greater expression of GPX1 in pre and post-symptomatic patient fibroblasts compared to healthy controls (Fig. 4F ), which correlates with increased binding of transcripts for these genes to hnRNP K protein (Fig. 4C ).
Altered expression of antioxidant genes in TDP-43 mutant cells
Activation of the Nrf2-ARE (antioxidant response element) pathway has been shown to be protective against oxidative stress- induced cell death. Numerous reports have suggested that the induction of Nrf2-regulated phase II enzymes, including HO-1 and NQO1 had strongly protective effects against oxidative damage and motor neuron cell death (40, 41) . To further evaluate the expression profile of Nrf2-associated antioxidants, we determined the protein expression of Nrf2, HO-1, GPx1 and Keap1 in control and TDP-43 M337V pre and post-symptomatic patient fibroblasts (Keap1 is an important modulator of the Nrf2-ARE pathway and sequesters Nrf2 in the cytoplasm in an inactive state). We observed increased Nrf2 protein in post-symptomatic fibroblasts compared to controls, and greatly elevated Nrf2 protein in all cell lines in response to sodium arsenite (Fig. 5A ). Despite this, and the elevated level of antioxidant transcripts downstream of Nrf2 signaling in response to sodium arsenite in patient fibroblasts (Fig. 4D-F) we did not observe significant changes in the expression of antioxidant proteins in response to sodium arsenite (Fig. 5A) . Glutathione (GSH) is an important antioxidant and its production is regulated by Nrf2-ARE signaling via modulation of GCLM and GCLC genes encoding the rate-limiting enzyme of GSH synthesis. GSH has a key role in cellular redox signaling and is protective against oxidative damage (42, 43) . Therefore, we determined if there are changes in the GSH content in cells where TDP-43 is mutated. As the major cell type associated with Nrf2 signaling is astrocytes, we examined the GSH content in primary astrocytes cultured from control and TDP-43 Q331K transgenic mice, as well as in patient fibroblasts. We observed a significant impairment in GSH induction in response to sodium arsenite levels in TDP-43 M337V patient fibroblasts compared to healthy controls (Fig. 5B) . We also observed similar impaired induction in GSH levels in response to sodium arsenite in primary astrocytes cultured from transgenic TDP-43 Q331K mice compared to control littermates (Fig. 5C ). These results demonstrated mutant TDP-43-associated impairment to Nrf2 and downstream antioxidant signaling. Therefore, we further examined the gene expression profile of additional antioxidant genes in the TDP-43 Q331K mouse model of ALS. We examined the transcript expression of antioxidant genes Nfe2l2 (Nrf2), Hmox1, Gclm and Nqo1 in spinal cord from WT and TDP-43 Q33IK transgenic mice, (Fig. 5D) . Overall, transgenic mice expressing mutant TDP-43 displayed a significant increase in transcripts of Hmox1 and Nqo1 in the spinal cord from transgenic mice compared to WT littermates. No significant increase in the expression of Gclm was evident in the spinal cord of transgenic mice. These findings suggest that TDP-43 mutation is associated with elevated oxidative stress, and this leads to upregulation of antioxidant genes. In contrast, no changes in the protein expression of GCLM, GPx1, and NQO1 were observed in TDP-43 Q33IK transgenic mice (Fig. 5E ). This result, along with attenuated GSH levels ( Lysates were immunoblotted for the indicated proteins, GAPDH was used as a loading control.
antioxidant response. HO-11 was elevated in Tg mice compared to WT counterparts (Fig. 5E ), possibly via Nrf2 independent pathways as there is evidence for Nrf2 independent HO-1 induction (44) (45) (46) . We next examined whether the abnormal antioxidant response due to mutant TDP-43 was associated with loss of hnRNP K from urea-soluble extracts. We measured Nrf2 protein expression in urea-soluble extracts from NSC-34 cells expressing mutant TDP-43 Q331K , which had previously shown loss of hnRNP K expression in the same extracts ( Supplementary  Material, Fig. S6B ). We found a modest increase in Nrf2 expression in the same TDP-43 Q331K extracts, compared to vector control and wild-type (normal) cells (Supplementary Material, Fig.  S10 ). The data may indicate that in some cellular compartments (yet to be determined), the level of hnRNP K expression may affect Nrf2 levels. It is not certain how this occurs but could be related to hnRNP K modulation of Nrf2 mRNA translation.
Depletion of hnRNP K does not affect antioxidant protein expression and glutathione levels
Finally, we examined whether hnRNP K is directly involved in modulating Nrf2 antioxidant signalling independent of TDP-43 mutation by using short interfering RNA (siRNA) targeted to hnRNP K to deplete levels of the protein in SH-SY5Y neuroblastoma cell line as previously reported by us (26) . siRNA against hnRNP K depleted levels of hnRNP K in transfected cells, while scrambled siRNA had no effect, (Supplementary Material, Fig.  S11A ). However, knock down of hnRNP K had no effect on the protein expression of antioxidants and GSH levels in response to sodium arsenite (Supplementary Material, Fig. S11A and B) . These data suggest that the impaired antioxidant response of TDP-43 mutant cells is driven not by a loss of hnRNP K protein or function, but rather a toxic gain of function. Refer to Fig. 6 for a proposed model for the toxic gain of function of hnRNP K in TDP-43 mutant cells.
Discussion
The aberrant expression, localization and accumulation of hnRNPs is a common feature of ALS. The hnRNPs A1, A2 and A3 have been investigated thoroughly in ALS and FTLD with mutations in hnRNPs A1 and A2 identified (10) . Mutations harbored in the PrLD of hnRNPs A1 and A2 accelerated fibrilization and the formation of cytoplasmic inclusions in an ALS mouse model (10) . In the study by Mori and colleagues (47), hnRNP A3 was found to interact with the hexanucleotide expanded repeat associated with C9orf72 and was reported to aggregate in proteinacious inclusions in the hippocampus of patients with C9orf72 mutations. The study by Mori and colleagues also found an interaction between hnRNP K and the C9orf72 hexanucleotide repeat (GGGGCC). These studies provide strong support for a common pathological process in ALS and FTLD with aberrant processing of hnRNPs. A study by Honda and colleagues investigated the expression of hnRNP A1 in ALS spinal cord motor neurons and it was clear that the expression of hnRNP A1 was diminished in the motor neurons displaying skein-like inclusions that also exhibited concomitant cytoplasmic aggregation of TDP-43 (48) . This disruption of key RNA binding proteins suggests that there may be disturbances to mRNA processing, which may contribute to the pathological features of ALS. hnRNP K has key roles in chromatin remodeling, transcription, splicing and translation processes and abnormal metabolism of the protein has been linked with several disorders including cancers and spinocerebellar ataxia type 10 (24,49,50) . In this neurological disorder, changes to hnRNP K metabolism appear to regulate the interaction of PKC delta with mitochondria, resulting in neuronal cell death (50) . hnRNP K also has important roles in neuronal development and axonogenesis suggesting that changes to its metabolism could have significant outcomes in neurological diseases (51) . We have previously reported that TDP-43 binds to hnRNP K in the cytosol (26) and we demonstrated that in human ALS spinal cord motor neurons, there was a global reduction to hnRNP K, which was clearly a prominent feature across the ALS tissue analysed compared to healthy controls (26) . As hnRNP K is a binding partner of TDP-43 (26), we hypothesized that mutations in TDP-43 may influence the expression of hnRNP K and the RNA binding properties of the protein, leading to the pathological features of ALS. In support of our hypothesis, we report that in cell models of ALS, mutations in TDP-43 (M337V or Q331K) resulted in attenuated gene expression of hnRNP K in response to sodium arsenite ( Fig. 1D and E) , this loss also occurred in parallel with attenuated hnRNP K in the cytoplasm and nucleus (basal expression) in mutant TDP-43 patient fibroblasts (Fig 2A, Supplementary  Material, Fig. S3A ) and in RIPA soluble and insoluble (urea) Given the prominent nuclear role of the proteins, the RNA binding properties of hnRNP A2 may be altered in TDP-43 proteinopathies.
We were able to identify a loss of insoluble hnRNP K in vivo in two ALS mouse models expressing TDP-43 Q331K and iTDP-43 A315T (Fig. 3B and D) . The fact that we can demonstrate that multiple mutations in TDP-43 appear to down regulate the expression of hnRNP K in particular fractions suggests that there is a disturbance in the cellular redistribution of hnRNP K which may be a common feature in TDP-43 mutant ALS cases. There was also concomitant loss of RIPA-insoluble TDP-43 in mutant bearing cells, (Fig. 2B, Supplementary Material, Fig. S6B ) suggesting that these proteins (TDP-43 and hnRNP K) display similar cellular dynamics in ALS. This is supported by the fact that these proteins are binding partners and also localize in stress granules as we have previously reported (26) . Nuclear material was entirely contained in the RIPA-insoluble extracts (as detected by histone H3 or lamin B1), therefore we see that in mutant patient fibroblasts and NSC-34 cells, there may be clearance of hnRNP K and TDP-43 from the nucleus and redistribution in the cytoplasm, recapitulating the pathological phenotype.
Although not evidenced directly in this study, it is possible that the disease pathology could ensue from unregulated cellular distribution of hnRNP K, therefore mutations in TDP-43 impact the functionality of the protein. hnRNP K is found in several subcellular compartments where it is thought to be involved in modulating multiple processes associated with gene expression. hnRNP K contains three K homology (KH) domains that mediate RNA-binding (52). Tahir and colleagues report that hnRNP K protein binds to mRNA encoding mitochondrial protein uncoupling protein-2 (UCP2) in endothelial cells (53) . UCP2 has antioxidant activity and can modulate redox homeostasis (54) . This interaction was modulated by angiopoietin-1 ligand stimulation of tyrosine phosphorylation on hnRNP K (53).
Via RNA binding immunoprecipitation studies, we have uncovered for the first time in ALS, an interaction between hnRNP K protein and antioxidant transcripts NFE2L2 and GPX1. To our knowledge, no such interaction has been reported and we provide evidence for robust enrichment of antioxidant transcripts bound to hnRNP K in mutant TDP-43 M337V patient fibroblasts under basal and stress conditions relative to healthy controls ( Fig. 4B and C) . Our data strongly suggest that mutation in TDP-43 influences this interaction and raises the possibility that the interaction may be mechanistically linked to disease. Alterations in Nrf2 expression and dysregulation of the Nrf2 signaling cascade could contribute to the chronic motor neuron degeneration in ALS and other neurodegenerative diseases. Indeed, Nrf2 signaling is impaired in the CNS of ALS patients (17) . Analyses of Nrf2 expression in primary motor cortex and spinal cord post-mortem tissue samples from ALS patients and controls demonstrated that there was a reduction of Nrf2 protein expression in motor neurons in ALS patients (22) . In this study, we did not observe attenuated Nrf2 expression in patient fibroblasts or NSC-34 TDP-43 mutant cells. However, we did demonstrate the lack of Nrf2-target protein upregulation (NQO1 and GPX1) in TDP-43 M337V patient fibroblasts in response to sodium arsenite (Fig. 5A ) and in Tg TDP-43 Q331K spinal cord tissue with the exception of HO-1, which was elevated in Tg mice (Fig. 5E) , possibly via Nrf2 independent pathways as there is evidence for Nrf2 independent HO-1 induction (44-46). The precise mechanism for the lack of Nrf2-target protein upregulation is unclear, however our results suggest that it may be due to a couple of potential scenarios, (i) GPX1 interaction with hnRNP K, renders GPX1 transcript (and potentially other antioxidants) in a translationally inactive state.
(ii) It may be related to the mislocalization of hnRNP K/antioxidant mRNA complexes. We have previously reported that both TDP-43 and hnRNP K accumulate in RNA stress granules in the cytosol during cell stress (26) . These changes potentially lead to the trapping of hnRNP K/antioxidant mRNA in stress granules and therefore loss of mRNA translation, therefore compromising antioxidant signaling and promoting oxidative stress in mutant TDP-43 fibroblasts and tissue.
We have demonstrated that TDP-43 M337V patient fibroblasts and astrocytes cultured from transgenic TDP-43 Q331K mice treated with sodium arsenite displayed attenuated levels of the antioxidant GSH compared to controls (Fig. 5B and C) . This indicates either an impairment in antioxidant signaling in mutant cells or a high level of cell stress in the mutant cells that cannot be compensated for by Nrf2 activation. This is consistent with published reports of reduced GSH in the motor cortex of patients with ALS (55) . Furthermore, although we observed an overall increase in the transcription of antioxidant genes in TDP-43 M337V patient fibroblasts and Tg mice spinal cord (Figs 4D-F, 5D), this elevated antioxidant gene transcription was not fully translated into protein ( Fig. 5A and E) . This provides further evidence that the mutant cells are undergoing an elevated oxidative stress response, however is functionally insufficient to compensate for the elevated stress.
The interaction of mRNA with hnRNP K is regulated by phosphorylation of the RNA-binding protein. There are multiple reports of increased tyrosine phosphorylation leading to release of specific mRNAs from hnRNP K (56, 57) . In addition, the RNA binding protein property of hnRNP K is positively regulated by serine/threonine phosphorylation (57) . Our previous work demonstrated a key process in control of TDP-43 trafficking in RNA stress granules involves phosphorylation of hnRNP K by CDK2 (and potentially additional CDKs) at Ser216 and/or Ser284 during cell stress (26) . This phosphorylation event may also be involved in modulating interactions of hnRNP K with NFE2L2 and Nrf2-regulated transcripts.
In this study, we were unable to demonstrate a direct association between the altered hnRNP K expression and antioxidant protein expression and glutathione levels (Supplementary Material, Fig. S11A and B) . However, this does not rule out a functional role for hnRNP K modulating antioxidant signaling as we can consider that i) the level of knock down may have been insufficient to demonstrate a direct role for hnRNP K modulating antioxidant signaling, ii) knockdown of hnRNP K may not affect antioxidant expression, however abnormal hnRNP K localization could induce these effects as demonstrated by the altered distribution of hnRNP K in RIPA insoluble (urea) extracts in TDP-43 mutant patient fibroblasts and in vivo, in TDP-43 Q331K and inducible TDP-43 (iTDP-43) A315T mutant mouse brain (Figs 2B, 3B and D). iii) A gain of toxic function of hnRNP K may ensue by virtue of hnRNP K binding to the antioxidant genes NFE2L2 and GPX1 ( Fig. 4B and C) , therefore impairing antioxidant signalling. iv) Additional hnRNPs such as hnRNPA1 or A2 may play a role, as redundancy is not uncommon for hnRNPs and other RNA binding proteins (58) . In some of our experiments, hnRNP A2 displayed similar changes to hnRNP K (Fig. 2B, Supplementary Material, Fig.  S3D ), however, direct binding of other hnRNPs to antioxidant transcripts has yet to be demonstrated. Our data suggest that the mislocalization of hnRNP K in the presence of TDP-43 mutations and aberrant binding to antioxidant transcripts is more likely to drive the impaired Nrf2 antioxidant response than simply a loss of hnRNP K protein and/or function. A proposed schematic of this model is presented in Fig. 6 .
In conclusion, our study provides strong evidence for altered hnRNP K expression and cellular distribution in ALS where TDP-43 is mutated. Elevated oxidative stress is a major pathological process in the ALS brain and spinal cord, therefore, further exploration of whether the interaction of hnRNP K (and potentially additional RNA binding proteins) with antioxidant genes is associated with ALS pathogenesis is clearly warranted. This may provide a basis for future development of therapeutics to target hnRNP K function in ALS.
Materials and Methods
Reagents
Sodium arsenite was from Sigma Aldrich (Sydney, NSW, Australia).
Polyclonal TDP-43 antisera (10782-2-AP) were purchased from Proteintech Group (Chicago, IL, USA) to TDP-43 (10782-2-AP). Polyclonal antisera to total and phosphorylated hnRNP K, total hnRNP A1, hnRNP A2, A3 were purchased from Abcam (Waterloo, Australia).
Patient fibroblast cultures
Patient fibroblasts were kindly provided by Professor Ian Blair, Macquarie University. Briefly, fibroblast cells were cultured from superficial skin biopsies of two neurologically healthy controls, and two individuals with a TDP-43 M337V mutation (29) .
Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM), containing 2 mM L-glutamine, 100U/mL penicillin, 100ug/ml streptomycin and 10% (vol/vol) heat inactivated fetalbovine serum in a humidified 37 C incubator with 5% CO 2 .
NSC-34 TDP-43 cell line
These are a neuronal cell line generated by the fusion of motor neuron enriched embryonic spinal cord cultures with a neuroblastoma cell line (40) . Cells were transfected with the pmCherry-N1 expression vector alone, the vector containing human wild-type TDP-43 (WT-TDP43) or mutant TDP-43 (TDP-43
Q331K
). The multiple cloning site of the pm-Cherry-N1 vector (Clontech Laboratories, Mountain View, USA) allows expression of fusion proteins on the N-terminus of the fluorescent mCherry protein (41) . Use of this vector therefore adds a fluorescent 29 kDa mCherry tag to the C-terminal end of the TDP43. Additional sequences in the vector include a Kozak consensus site to enhance translational efficiency (42) , an SV40 origin for replication in mammalian cells, a pUC origin for propagation in E. coli, and SV40 polyadenylation signals. The vector also contains a neomycin resistance cassette, which was utilized to select stably transfected cells by growing cells in media supplemented with G418 for 2 weeks. Limiting dilution was used to generate monoclonal cell lines. Stably transfected lines were maintained in DMEM media (25 mM glucose) supplemented with 10% (v/v) FBS, penicillin/streptomycin and G418.
SH-SY5Y cell line
Neuroblastoma SH-SY5Y cell line was passaged and maintained in DMEM/F12 plus 10% fetal bovine serum (FBS), 50 units/ml penicillin and 50 mg/ml streptomycin. Cells were maintained in 5% CO 2 at 37 C.
Animal experimentation C57BL/6 control and transgenic mice expressing myc-tagged human TDP-43 modified to harbour the ALS linked Q331K mutation (TDP-43
Q331K
) under the mPrP were obtained from The Jackson laboratoryV R as previously described (32) . RIPA and Urea brain extracts from 1, 4.5 and 6-month old non-transgenic (wild-type) and pTRE-TDP-43 A315T expressing mice were kindly provided by Prof Lars M. Ittner and Dr Yazi D Ke (University of NSW, Sydney) as previously reported (34) . All animal experiments were approved by the Animal Ethics Committee, The University of Melbourne.
Primary neonatal astrocyte cell cultures
Primary astrocyte cultures were prepared from neonatal mice as published previously (59) . Briefly, brains removed from newborn wild-type and TDP-43 Q331K mouse pups were mechanically dissociated by sequential passes through 250 and 135 lm nylon mesh, centrifuged at 500 Â g for 5 min before resuspension in DMEM supplemented with 50 U/ml penicillin-streptomycin and 10% FBS and plated at 160,000 cells/cm 2 .
Human sample collection and hnRNP K gene expression analysis RNA was available from The Mayo Clinic, and was used to determine the mRNA levels of hnRNP K by qRT-PCR. For a detailed list of cases analysed refer to reference (35) .
RNA isolation and cDNA synthesis
Total RNA was extracted from patient fibroblasts, NSC-34 cells, and TDP-43 wild-type and TDP-43 Q331K spinal cord using Trizol reagent (Thermo Fisher Scientific) according to manufacturer's instructions. RNA concentrations were measured using the QubitV R 2.0 fluorometer (Life Technologies). RNA (200 ng) was reverse transcribed using random hexamers and High Capacity cDNA kit (Life Technologies).
Quantitative RT-PCR (qRT-PCR)
TaqMan Gene Expression assays for human or mouse HNRNPK, HNRNPA1, HNRNPA2, HNRNPA3, EGR1, NFE2L2, HMOX1, GCLM, NQO1, GPX1 and GAPDH were purchased from Thermo Fisher Scientific and performed according to manufacturer's instructions. Each reaction mix contained 0.5 ml of Taqman Gene Expression assays containing FAM-labeled probes, 5 ml of 2Â TaqMan Fast Advance Gene Expression Master mix and 4 ml of cDNA template (synthesized from 10 ng RNA per reaction). Duplicate reactions were performed using the LightCycler 480 (Roche) under conditions recommended by the manufacturer. Cycle threshold (Ct) values were calculated as the lowest cycle number producing an exponential increase in PCR product amplification. Delta Ct method was used for normalization of expression relative to GAPDH.
RIPA and urea extraction from cell lines and brain tissue
To generate RIPA soluble and RIPA insoluble (Urea soluble) extracts, proteins were extracted as previously described (34) 
Cytoplasm and nuclear extraction from cell lines
To generate cytoplasm and nuclear extracts, cells were lysed in Triton-X-100 lysis buffer containing 50mM Tris-HCL pH 7.5, 0.5% Triton-X-100, 137.5 mM NaCl, 10% glycerol, 1mM Sodium vanadate, 50mM Sodium fluoride, 10mM Sodium pyrophosphate, 5 mM EDTA and supplemented with protease inhibitor cocktail (Roche).
To separate insoluble nuclei, cells were centrifuged at 15, 000 g for 15 min at 4 C. The supernatant containing the cytoplasmic fraction was separated and pellets were washed with Triton-X-100 lysis buffer, centrifuged for 5 min at 4 C and resuspended in
Triton-X-100 lysis buffer with 0.5% SDS. Genomic DNA was sheared by sonication, centrifuged at 15, 000 g for 15 min at 4 C with the supernatant yielding the nuclear extracts. The purity of cytoplasm and nuclear extracts was verified by Western blot analysis for GAPDH and Histone H3 respectively.
Western blot analysis of protein expression and phosphorylation
Cell lysates prepared in Phosphosafe Extraction Buffer (Merck) at an equal protein concentration were mixed with electrophoresis SDS sample buffer and separated on 12% SDS-PAGE TrisGlycine gels. Proteins were transferred to PVDF membranes and blocked with 5% skim milk solution in PBST before immunoblotting. Membranes were probed with polyclonal antisera against TDP-43 pan or human specific (Proteintech) total or phosphohnRNP K, hnRNP A1, hnRNP A2, hnRNP A3, FUS, GPX1, GCLM and NQO1 (Abcam), Lamin B1, Histone H3, Nrf2, HO-1, Keap1 (Cell Signaling). Secondary antiserum was rabbit-HRP, mouse-HRP or goat-HRP at 1:5,000 dilution. Blots were developed using GE Healthcare ECL Advance Chemiluminescence (Rydelmere, NSW, Australia) and imaged on a Fujifilm LAS3000 imager (Berthold, Bundoora, Victoria, Australia). Expression of GAPDH or b-actin (Cell Signaling) was determined using antisera at 1:5,000 for protein loading controls where necessary.
RNA-binding protein immunoprecipitation
To purify RNA bound to the hnRNP K protein in human fibroblasts, the Magna RIP TM RNA-Binding Protein Immunoprecipitation Kit (Millipore) was used. Briefly, human fibroblasts were collected and lysed in 200 ml RIP lysis buffer supplemented with protease inhibitor and RNase inhibitor. After 5min of incubation on ice, 50 mL of magnetic bead suspension was transferred to each tube. The beads were washed two times using 500 mL of RIP wash buffer, 5 mg of immunoprecipitation grade anti-hnRNP K antibody (Abcam) was added to the beads and incubated at RT for 30 min. The beads were washed three times with wash buffer, and then resuspended in 900 ml of RIP immunoprecipitation buffer (0.5 M EDTA, RNase inhibitor, and RIP wash buffer). The cleared RIP lysate was added to the antibody-bead complex and incubated overnight at 4 C.
RNA was purified using proteinase K buffer (RIP wash buffer, 10% SDS, and 10 mg/ml proteinase K) and precipitated with Salt Solution I, Salt Solution II, Precipitate Enhancer and absolute ethanol. The isolated RNA from RIP was analysed by qRT-PCR and RT 2 PCR neurodegeneration custom array (Qiagen). The results were expressed as the relative fold enrichment of the target precipitation as compared with the rabbit IgG negative control.
PCR neurodegeneration array
RNA purified from the Magna RIP TM RNA-Binding Protein
Immunoprecipitation Kit (Millipore) was converted into cDNA using the RT 2 First Strand Kit (Qiagen). The quality of cDNA was confirmed by using an RT 2 RNA QC PCR Array Kit (Qiagen). The cDNA was then added to the RT 2 SYBR Green qPCR Master Mix (Qiagen). Each sample was aliquotted on a customised PCR array for common genes associated with neurodegeneration according to the manufacturer's instructions (Qiagen). A total of 92 genes related to the PCR array were analysed along with internal controls by using an RT 2 Profiler TM PCR Array Kit in a 384-well format (Light Cycler 480, Roche). Data were processed by the DDCt method using proprietary tools supplied by SABiosciences PCR Data Analysis Web Portal (Qiagen). The samples were analysed only if the test passed all the quality controls, including RT efficiency and lack of DNA contamination. Data were calculated as fold differences relative to IgG Rabbit negative control and expressed as fold enrichment.
Knock down of hnRNP K by siRNA SH-SY5Y cells were cultured in antibiotic-free media 24h prior to transfection. The following day, cells were washed twice with Opti-MEM media and incubated in Opti-MEM media for 30min to condition cells. Cells were transfected with negative siRNA or siRNA targeting hnRNP K (OriGene) using DharmaFECT 1 transfection reagent (Thermo Scientific) in antibiotic free media to a final concentration of 10nM. Cells were harvested 72h post transfection for western blot analysis and GSH assays.
Glutathione (GSH) assay
Glutathione content was determined according to the method of Tietze (60) as described previously (59) . For determination of cellular glutathione, 10 ll samples of cell lysates in 1% sulfosalicylic acid were analyzed. For media analysis, one part medium was combined with one part water and two parts 1% sulfosalicylic acid, and 20 ll of this was analyzed. Following the addition of reaction mix to a final concentration of 200 lM NAPDH, 150 lM 5,5 0 -dithiobis-(2-nitrobenzoic acid), and 0.1 U glutathione reductase (Sigma-Aldrich) in 50 mM NaP i buffer pH 7.5 containing 0.5 mM EDTA, the rate of thionitrobenzoate production was followed spectrophotometrically at 405 nm. Fluorescence activated cell sorting. Cell death was quantified by staining with propidium iodide (2.5 lg/ml), followed by flow cytometric analysis in a FACScan (Becton Dickinson). In each sample 10,000 events were measured, and the survival (% PInegative cells) quantified as previously described (26) .
Statistical analysis
All data described in graphical representations are mean 6 standard error of the mean (SEM) of three or more separate experiments unless stated otherwise. The results were analysed using a Student's t-test, one-way ANOVA or a two-way ANOVA as appropriate.
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